|
Market Closed -
Nasdaq
21:00:00 14/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 18.42 USD | +4.96% |
|
+4.63% | +5.32% |
| 09-09 | Summit Therapeutics Shares Rise After Upgrade From Jefferies | MT |
| 09-09 | Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 | MT |
Company Valuation: Summit Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,436 | 10,512 | 10,021 | 10,901 | - | - |
| Change | - | 631.97% | -4.67% | 8.78% | - | - |
| Enterprise Value (EV) 1 | 1,436 | 10,512 | 9,493 | 10,434 | 10,702 | 10,605 |
| Change | - | 631.97% | -9.69% | 9.91% | 2.58% | -0.91% |
| P/E | -2.62x | -58.1x | -12.2x | -15.8x | -15.8x | -27.4x |
| PBR | - | - | 20.7x | 54x | 547x | 34.1x |
| PEG | - | 0.8x | -0x | 0.8x | -135.33x | 0.6x |
| Capitalization / Revenue | - | - | - | 3,730x | 261x | 25.5x |
| EV / Revenue | - | - | - | 3,570x | 257x | 24.8x |
| EV / EBITDA | - | -96.9x | -11.7x | -18.3x | -19.6x | -34x |
| EV / EBIT | - | -58.8x | -11.7x | -15.7x | -15x | -23.9x |
| EV / FCF | - | -93.4x | -39.6x | -18.4x | -15.5x | -19.2x |
| FCF Yield | - | -1.07% | -2.52% | -5.43% | -6.45% | -5.22% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.7828 | -0.2452 | -1.066 | -0.8651 | -0.8661 | -0.4991 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 2.923 | 41.7 | 427.4 |
| EBITDA 1 | - | -108.4 | -810.4 | -571.6 | -547 | -311.8 |
| EBIT 1 | - | -178.8 | -810.5 | -665.3 | -715.4 | -444.4 |
| Net income 1 | -486.2 | -175.1 | -799.5 | -691.3 | -733.6 | -427.1 |
| Net Debt 1 | - | - | -528.6 | -467.3 | -198.6 | -296.3 |
| Reference price 2 | 2.05 | 14.25 | 13.00 | 13.66 | 13.66 | 13.66 |
| Nbr of stocks (in thousands) | 700,843 | 737,448 | 771,150 | 797,750 | - | - |
| Announcement Date | 20/02/24 | 24/02/25 | 23/02/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.8x | 3569.89x | -18.25x | -.--% | 14.69B | |
| 20.63x | 7.28x | 14.62x | 1.44% | 70.24B | |
| 32.28x | 9.34x | 45.05x | 0.04% | 62.63B | |
| -76.7x | 14.8x | -71.37x | -.--% | 27.36B | |
| 29.77x | 6.32x | 16.41x | -.--% | 25.71B | |
| -15.03x | 5.62x | -7.06x | -.--% | 24.83B | |
| 26.45x | 5.03x | 16.73x | -.--% | 19.52B | |
| 44.88x | 16.47x | 33.42x | 0.34% | 15.51B | |
| 1267.62x | 36.68x | 797.93x | -.--% | 14.66B | |
| 17.36x | 5.16x | 12.06x | -.--% | 13.93B | |
| Average | 133.15x | 367.66x | 83.95x | 0.18% | 28.91B | |
| Weighted average by Cap. | 74.63x | 191.03x | 50.46x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SMMT Stock
- Valuation Summit Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
